Original research: Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII)

BMJ Open Ophthalmology

article

Rui Wang¹  Cynthia K McClard²  Stephen Laswell⁴  Raziyeh Mahmoudzadeh⁵  Mirataollah Salabati⁵  Michael Ammar⁵  Jordyn Vannavong⁶  Aamir A Aziz⁷  Amy Ewald⁸  Allison V Calvanese⁸  Erik B Lehman⁹  Sagit Fried^1,10  Victoria Windham^1,11  Adriana Strutt^1,11  Namrata Saroj^1,12  Arshad Mohammad Khanani⁶  David A Eichenbaum⁸  Carl Regillo⁵  Charles Clifton Wykoff⁴ 

[1] Ophthalmology , Penn State College of Medicine;Ophthalmology , Dean McGee Eye Institute;The University of Oklahoma Health Science Center;Retina Consultants of Texas;Mid Atlantic Retina Service , Wills Eye Hospital;Sierra Eye Associates;University of Nevada Reno School of Medicine;Retina Vitreous Associates of Florida;Department of Public Health Sciences , Penn State Health Milton S Hershey Medical Center;Ben-Gurion University of the Negev;Neurology , Baylor College of Medicine;All Eyes Consulting;Ophthalmology , Morsani College of Medicine at the University of South Florida;Blanton Eye Institute

关键词: Retina;    Treatment other;   

DOI  :  10.1136/bmjophth-2022-001188

学科分类：工业工程学

来源: BMJ Publishing Group

【 摘 要 】

Aim To quantify the areas of burden experienced by patients requiring repeated intravitreal injections (IVI) in the management of exudative retinal diseases.Methods The validated Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections survey was administered to patients at four retina clinical practices across four US states. The primary outcome measure was Treatment Burden Score (TBS), a single score assessing overall burden.Results Of 1416 (n=657 age-related macular degeneration; n=360 diabetic macular oedema/diabetic retinopathy; n=221 retinal vein occlusion; n=178 other/uncertain) patients, 55% were women with an average age of 70 years. Patients most frequently reported receiving IVI every 4–5 weeks (40%). The mean TBS was 16.1±9.2 (range 1–48; scale of 1–54), and the TBS was higher in patients with diabetic macular oedema and/or diabetic retinopathy (DMO/DR) (17.1) compared with those with age-related macular degeneration (15.5) or retinal venous occlusive (15.3) (p=0.028). Though the mean level of discomfort was quite low (1.86) (scale 0–6), 50% of patients reported experiencing side effects more than half of the visits. Patients having received fewer than 5 IVI reported higher mean anxiety levels before (p=0.026), during (p=0.050) and after (p=0.016) treatment compared with patients having received more than 50 IVI. After the procedure, 42% of patients reported restrictions from usual activities due to discomfort. Patients reported a high mean satisfaction rating of 5.46 (scale 0–6) with the care of their diseases.Conclusions The mean TBS was moderate and highest among patients with DMO/DR. Patients with more total injections reported lower levels of discomfort and anxiety but higher disruption to daily life. Despite the challenges related to IVI, the overall satisfaction with treatment remained high.

【 授权许可】

CC BY-NC|CC BY|CC BY-NC-ND